Royal Bank of Canada’s Kazia Therapeutics KZIA Stock Holding History

Royal Bank of Canada’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Sell	34,340 -19,793	-37%	-$138K	﹤0.01%	4559
2025 Q4	$373K	Buy	+54,133	New	+$461K	﹤0.01%	4376
2022 Q3	–	Sell	-20	Closed	-$4K	–	7649
2022 Q2	$4K	Hold	20	–	–	﹤0.01%	6730
2022 Q1	$8K	Buy	+20	New	+$7.15K	﹤0.01%	7056
2021 Q4	–	Sell	-1	Closed	-$1K	–	7792
2021 Q3	$1K	Buy	+1	New	+$491	﹤0.01%	7480
2018 Q3	–	Sell	-25	Closed	-$4K	–	6829
2018 Q2	$4K	Hold	25	–	–	﹤0.01%	6102
2018 Q1	$7K	Hold	25	–	–	﹤0.01%	5833
2017 Q4	$4K	Hold	25	–	–	﹤0.01%	6129
2017 Q3	$4K	Hold	25	–	–	﹤0.01%	6461
2017 Q2	$5K	Hold	25	–	–	﹤0.01%	6039
2017 Q1	$7K	Buy	25 +24	+2,400%	+$7.56K	﹤0.01%	6102
2016 Q4	$0	Buy	+1	New	+$335	﹤0.01%	6703
2016 Q2	–	Sell	-1	Closed	–	–	6451
2016 Q1	$0	Buy	+1	New	+$422	﹤0.01%	6521
2015 Q3	–	Sell	-70	Closed	-$56K	–	6714
2015 Q2	$56K	Buy	+70	New	+$79.4K	﹤0.01%	5163

Other funds holding KZIA

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada's KZIA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Kazia Therapeutics (KZIA) stake by 37% in Q1 2026, selling an estimated $138K and leaving 34,340 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #4559.

Royal Bank of Canada first reported a position in KZIA in Q2 2015 and has held it in 14 quarters since. The position peaked at $373K in Q4 2025. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

Royal Bank of Canada held 34,340 shares of Kazia Therapeutics worth $255K as of Q1 2026.
Royal Bank of Canada sold 19,793 Kazia Therapeutics shares in Q1 2026, an estimated $138K.
Kazia Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4559 holding.
Royal Bank of Canada first reported a position in Kazia Therapeutics in Q2 2015 and has held it in 14 quarters since.
Royal Bank of Canada's Kazia Therapeutics position peaked at $373K in Q4 2025.
23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.